MicroPort CardioFlow Medtech (HKG:2160) expects a net loss of between 30 million yuan and 60 million yuan in 2024, representing a decline of 87% to 94% from a year prior, according to a Thursday filing.
The medical device maker attributed the forecast to the advancement of commercialization of certain products, higher overseas revenue, cost management, reversal of an impairment loss on an equity investment, and fair value gains on convertible instruments.
Shares of the company were up 7% in recent trade.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.